AIM ImmunoTech Inc (NYSEAMERICAN:AIM) has announced that it has received a statistically significant promising pancreatic cancer survival results from its multi-year Early Access Program that was carried at Erasmus University Medical Centre, Netherlands.
Positive results from ampligen use in advanced pancreatic cancer
According to leading global pancreatic cancer expert and oncologist Prof. Casper van Eijck, there were significantly positive survival results following the use of Ampligen in locally metastatic/advanced pancreatic cancer patients following systemic chemotherapy. Van Eijck and his Erasmus MC team compared overall survival in the experimental group to a late historical control group matched for gender, age, stage of disease progression, and the number of Folfirinox chemotherapy cycles.
Results demonstrated a higher median survival of almost 200% in the group that received ampligen relative to historical cohorts. The results obtained a statistically higher degree of significance. Van Eijck said that according to the data, there is potential that ampligen could offer a meaningful extension to the current standard of care (SOC) for the planned study in advanced pancreatic cancer. He is currently preparing a detailed clinical report of the study with publication expected soon.
AIM to carry follow-up of Phase2/3 study
The company’s CEO Thomas K. Equels stated that they started the program at the beginning of 2017, and the results from the study conducted at Erasmus have exceeded the company’s optimistic expectations. He lauded the work of Van Eijck and his team and myTommorows’ guiding hand Ronald Brus for their careful diligence and vision in implementation of the important analysis of Ampligen as a single therapy for advanced pancreatic cancer. He added that they were proud of the Netherlands’ government for its commitment and support to advance innovation for this type of cancer that has limited treatments.
The company will now work with Amarex Clinical Research LLC, it’s Contract Research Organisation in seeking a fast track and FDA breakthrough designation and also IND approval for the Phase 2/3 clinical trial, which is a follow-up study. The follow-up study will be at Erasmus MC and major cancer centers in the US.
